ElliottFWintonMD

Hematology • Atlanta, GA

Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine

Join to view full profile

Dr. Winton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Winton's full profile

Already have an account?

Office
1365 Clifton Rd Ne
Atlanta, GA 30322
Phone+1 404-778-1900
Is this information wrong?

Education & Training

Emory University School of MedicineResidency, Internal Medicine, 1973 - 1974
Emory University School of MedicineResidency, Internal Medicine, 1970 - 1973
University of ChicagoInternship, Internal Medicine, 1967 - 1968
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1967

Certifications & Licensure

GA State Medical License 1972 - 2025
OH State Medical License 1968 - 1974
American Board of Internal Medicine Internal Medicine

Clinical Trials

Correlative Biomarker Study in Patients With Myeloproliferative Disorders Start of enrollment: 2007 Apr 01
Completed
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Start of enrollment: 2011 May 01
Completed
Phase 2
Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis Start of enrollment: 2013 Nov 01
Terminated
Phase 2
Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Start of enrollment: 2014 Jul 08
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice S Wang, Aaron T Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati G...> ;Blood Advances. 2024 Mar 26
MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis...
Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice Wang, Aaron Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, S...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
34 citations
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
John Mascarenhas, Heidi E Kosiorek, Josef T Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Abdulraheem Yacoub, Claire N Harrison, Mary Frances McMullin, Alessandro M V...> ;Blood. 2022 May 12
58 citations
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
DeAngelo, D., Radia, D., George, T., Robinson, W., Quiery, A., Drummond, M., Bose, P., Hexner, E., Winton, E., Horny, H., Tugnait, M., Schmidt-Kittler, O., Evans, E., ...> ;Nature Medicine. 2021 Dec 1
12 citations
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia.
Anand Jillella, Martha Arellano, Manila Gaddh, Amy A. Langston, Leonard T. Heffner, Elliott F. Winton, Morgan L. McLemore, Chao Zhang, Catherine R. Caprara, Kathryn Sa...> ;JCO Oncology Practice. 2021 Apr 1
8 citations
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
Alexander Coltoff, Ruben A. Mesa, Jason Gotlib, Jessica Shulman, Raajit K. Rampal, Olivia Siwoski, Abdulraheem Yacoub, Alison R. Moliterno, Anna Yang, Evan M. Braunste...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 May 29
5 citations
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.
Jee Hyun Kong, Elliott F. Winton, Leonard T. Heffner, Manila Gaddh, Brittany Hill, Jessica Neely, Angela Hatcher, Meena Joseph, Martha Arellano, Fuad El-Rassi, Audrey ...> ;Journal of Clinical Medicine. 2020 May 20
57 citations
Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia
Kim Hien T. Dao, Jason Gotlib, Michael M.N. Deininger, Stephen T. Oh, Jorge E. Cortes, Robert H. Collins, Elliot F. Winton, Dana R. Parker, Hyunjung Lee, Anna Reister ...> ;Journal of Clinical Oncology. 2020 Apr 1
108 citations
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Abdulraheem Yacoub, John Mascarenhas, Heidi E. Kosiorek, Josef T. Prchal, Dmitriy Berenzon, Maria R. Baer, Ellen K. Ritchie, Richard T. Silver, Craig M. Kessler, Ellio...> ;Blood. 2019 Oct 31
18 citations
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
John Mascarenhas, Heidi E. Kosiorek, J. T. Prchal, Abdulraheem Yacoub, Dmitriy Berenzon, Maria R. Baer, Ellen K. Ritchie, Richard T. Silver, Craig M. Kessler, Elliot F...> ;Leukemia. 2019 Jul 30
58 citations
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease
H Khoury, Amelia A. Langston, Vamsi Kota, Jennifer A. Wilkinson, Iskra Pusic, Anand Jillella, Stephanie Bauer, Audrey S Kim, Danielle Roberts, Zaid Al-Kadhimi, Imre Bo...> ;Bone Marrow Transplantation. 2018 Jul 1
175 citations
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Claire N. Harrison, Alessandro M. Vannucchi, Uwe Platzbecker, Francisco Cervantes, Vikas Gupta, David Lavie, Francesco Passamonti, Elliott F. Winton, Hua Dong, Jun Kaw...> ;The Lancet. Haematology. 2017 Jan 1
2 citations
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib
Vamsi Kota, Jee Hyun Kong, Martha Arellano, Fuad El Rassi, Manila Gaddh, Leonard T. Heffner, Elliott F. Winton, Anand Jillella, Morgan L. McLemore, H. Jean Khoury> ;Clinical Lymphoma, Myeloma & Leukemia. 2017 Dec 1
199 citations
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Ruben A. Mesa, Jean-Jacques Kiladjian, John Catalano, Timothy Devos, Miklos Egyed, Andrzei Hellmann, Donal McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronal...> ;Journal of Clinical Oncology. 2017 Sep 20
214 citations
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, ...
Claire N. Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Ramon V. Tiu, Pierre Zachee, Eric Jourdan, Elliott F. Winton, Richard T. Silver, ...> ;The Lancet. Haematology. 2017 Jul 1
12 citations
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia
Jee Hyun Kong, Elliott F. Winton, Leonard T. Heffner, Zhengjia Chen, Amelia Langston, Brittany Hill, Martha Arellano, Fuad El-Rassi, Audrey S Kim, Anand Jillella, Vams...> ;Cancer. 2017 Jul 1
300 citations
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, E...> ;Journal of Hematology & Oncology. 2017 Feb 22
83 citations
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
John Mascarenhas, Moshe Talpaz, Vikas Gupta, Lynda Foltz, Michael R. Savona, Ronald Paquette, A. Robert Turner, Paul Bernard Coughlin, Elliott F. Winton, Timothy Burn,...> ;Haematologica. 2017 Feb 1
10 citations
Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia
Elliott F. Winton, Vamsi Kota> ;Future Oncology. 2017 Feb 1
2 citations
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma
Jonathon B. Cohen, Silvana Z. Bucur, Elliott F. Winton, Rajni Sinha, Leonard T. Heffner, Nassoma King, Sagar Lonial, Amelia Langston, Edmund K. Waller, Amanda Hutchiso...> ;Clinical Lymphoma, Myeloma & Leukemia. 2015 Sep 1
11 citations
Ruxolitinib for the treatment of patients with polycythemia vera
Jean-Jacques Kiladjian, Elliott F. Winton, Moshe Talpaz, Srdan Verstovsek> ;Expert Review of Hematology. 2015 Jul 7
80 citations
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Richard S Levy, Vikas Gupta, John F DiPersio, John V Catalano, Michael W N Deininger, Carole B Miller, Richard T Silver, ...> ;Haematologica. 2015 Apr 1
13 citations
Predicting early blast transformation in chronic-phase chronic myeloid leukemia: Is immunophenotyping the missing link?
Fuad El Rassi, John Bergsagel, Martha Arellano, Manila Gaddh, Anand Jillella, Vamsi Kota, Leonard T. Heffner, Elliott F. Winton, Hanna Jean Khoury> ;Cancer. 2015 Mar 15
1 citations
Incidence and geographic distribution of adult acute leukemia in the state of Georgia.
Fuad El Rassi, Kevin C. Ward, Christopher R. Flowers, Leonard T. Heffner, Edmund K. Waller, Elliott F. Winton, Jennifer E. Vaughn, Brittany G. Hill, Amelia A. Langston...> ;Southern Medical Journal. 2014 Aug 1
19 citations
Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma
Zahi Mitri, Momin T. Siddiqui, Fuad El Rassi, Jeannine T. Holden, Leonard T. Heffner, Amelia Langston, Edmund K. Waller, Elliott F. Winton, Morgan L. McLemore, Leon Be...> ;Leukemia & Lymphoma. 2014 May 2
Join now to see all

Abstracts/Posters

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
Elliott F. Winton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019